FIND2CURE
FIND2CURE
We imagine a world in which every cancer patient receives the best possible care. For us, research is merely a means to a far more significant end – a patient that has been successfully treated. We are ushering in a future where the relationship of molecular profiles and gene-drug therapies is completely integrated, resulting in better patient results and quicker drug approvals, in collaboration with our partners.”
Every cancer patient, we believe, is entitled to know if their tumour contains actionable mutations. Our flagship tool, F2C-NGS, is a robust genomic profiling test with the industry's lowest tumour tissue criteria, allowing more patients to receive the results and treatments they need in timely and cost-effective manner.
Our mission is to provide each patient with the best possible care. We have a portfolio of convincing clinical trials alongside our test results so that patients can get access to their best care, which could be investigational. Patients would have more care options near to home since these trials are available locally.
We're building a data-driven learning loop that produces and applies data to fuel new treatment insights and biomarker discovery. Our team of physicians, scientists, and engineers is constantly learning from the most recent clinical-molecular data in order to develop more effective biomarker-guided treatment hypotheses. We then collaborate with biopharmaceutical companies to get those drugs to patients.
We offer a comprehensive precision oncology approach that enables health systems to become unique cancer care providers.
By developing novel cancer diagnostics that inform customized treatment choices, we hope to improve patient care.
Biopharmaceutical companies will use our platform to design and perform groundbreaking biomarker-guided studies.
Personalized Medicine and Acceleration
Early Detections, Prevention and Management
Participate in Private & Govt Grants
